ONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metastases
SAN DIEGO, May 23, 2019 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a pr… […]
– Triggers $10 million milestone payment to Halozyme in the second quarter –
SAN DIEGO, May 22, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today anno… […]
Early data on pancreatic cancer detection presented at Digestive Disease Week® 2019
SAN DIEGO, May 20, 2019 /PRNewswire/ — Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Scien… […]
Presentation to Highlight Positive Data Demonstrating Clinical and Biomarker Activity Suggesting Localized Target Engagement and Minimal Systemic Exposure Following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colit… […]
SAN DIEGO, May 7, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet pa… […]
SAN DIEGO, April 24, 2019 /PRNewswire/ — Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a res… […]
First Conditionally Active Biologics licensing participation in Greater China territory
SAN DIEGO, April 16, 2019 /PRNewswire/ — BioAtla ®, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biolog… […]
— Adding the New Trait to Cibus Herbicide-Tolerant Germplasm Results in Cibus’ First “Stacked” Non-Transgenic Traits
SAN DIEGO, April 1, 2019 /PRNewswire/ — Cibus, a leader in advanced plant-breeding technologies, today announced it has licensed to… […]
SAN FRANCISCO and SAN DIEGO, March 21, 2019 /PRNewswire/ — Trianni, Inc. (“TRIANNI”) and San Diego Biomedical Research Institute (“SDBRI”) jointly announced today that they have entered into a license agreement for the use of the Trianni Mouse®, a … […]
Saint John’s and John Wayne Cancer Institute to validate use of cerebrospinal fluid with the Company’s Target Selector(TM) assay platform in patients with known or suspected brain metastases
SAN DIEGO, Feb. 27, 2019 /PRNewswire/ — Biocept, Inc. (NAS… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
